JEOL (6951) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
13 Aug, 2025Executive summary
Net sales rose 10.4% year-over-year to ¥40,145 million for the quarter ended June 30, 2025, with operating profit up 42.1% to ¥5,792 million and profit attributable to owners up 19.9% to ¥4,669 million.
Basic earnings per share increased to ¥91.32 from ¥76.26 year-over-year.
Financial highlights
Gross profit improved to ¥19,451 million from ¥18,199 million year-over-year, with gross margin rising slightly.
Operating profit margin increased, supported by higher sales and controlled SG&A expenses.
Total assets stood at ¥220,172 million, with an equity-to-asset ratio of 62.4% as of June 30, 2025.
Net assets per share rose to ¥2,687.52 from ¥2,672.19 at the previous fiscal year-end.
Outlook and guidance
Full-year net sales forecast at ¥181,000 million, down 8.0% year-over-year; operating profit expected to decline 10.0% to ¥24,000 million.
Profit attributable to owners projected at ¥18,000 million, a 3.7% decrease year-over-year.
No revisions to previously announced earnings or dividend forecasts.
Latest events from JEOL
- Revenue and profit fell, but financial stability and growth initiatives were maintained.6951
Q3 202613 Feb 2026 - Vertical argon ion etching delivers uniform, high-resolution depth profiling with minimal roughness.6951
Status update10 Feb 2026 - Sales and profits fell year-over-year, but Medical Equipment outperformed and dividends remain robust.6951
Q2 20269 Dec 2025 - Strong sales growth and margin expansion drive upward revision to full-year outlook.6951
Q2 202513 Jun 2025 - Revenue and profit surged in Q1 FY2025, led by robust equipment demand; outlook unchanged.6951
Q1 202513 Jun 2025 - Record sales and profit, but lower net income and cautious outlook for next year.6951
Q4 20256 Jun 2025 - Record profits and sales driven by robust equipment demand and margin gains.6951
Q3 20255 Jun 2025